Injectable microencapsulated islet cells as a bioartificial pancreas

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Materials Science

Background:

• Type 1 diabetes mellitus presents a significant challenge requiring effective islet transplantation.
• Encapsulation of pancreatic islets aims to prevent immune rejection and prolong graft survival.
• Previous encapsulation methods using polyethyleneimine induced inflammatory responses, limiting efficacy.

Purpose of the Study:

• To evaluate the long-term efficacy of alginate-polylysine-alginate encapsulated islets for diabetes treatment.
• To assess the biocompatibility and structural integrity of the hydrogel membranes post-transplantation.
• To investigate the potential of biocompatible hydrogel membranes for clinical cell therapy.

Main Methods:

• Rat islets were encapsulated in alginate-polylysine-polyethyleneimine and alginate-polylysine-alginate membranes.
• Encapsulated islets were transplanted into diabetic recipient rats.
• Normoglycemia and graft survival were monitored over an extended period.
• Scanning Electron Microscopy (SEM) was used to analyze capsule membrane structure.

Main Results:

• Alginate-polylysine-polyethyleneimine encapsulation led to inflammatory responses and limited graft function.
• Alginate-polylysine-alginate encapsulated islets restored normoglycemia for up to 10 months.
• Viable encapsulated islets were recovered 5 months post-transplantation.
• SEM confirmed smooth hydrogel membrane surfaces with a thickness of 4.00 +/- 0.28 microns.

Conclusions:

• Biocompatible alginate-polylysine-alginate hydrogel membranes support long-term islet viability and function.
• This encapsulation strategy overcomes the inflammatory issues associated with polyethyleneimine.
• Cell encapsulation in biocompatible hydrogel membranes shows significant clinical potential for treating diabetes.